Improving treatment for people with HIV who smoke and drink alcohol in Kenya
Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol use among PWH in Nairobi, Kenya
This study is looking for ways to help people living with HIV in Nairobi, Kenya, cut down or quit smoking and drinking alcohol by combining counseling and medication, so they can live healthier lives and lower their risk of serious diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11007953 on NIH RePORTER |
What this research studies
This research focuses on addressing the high rates of tobacco and alcohol use among people living with HIV (PWH) in Nairobi, Kenya. It aims to develop and optimize treatment strategies that combine behavioral counseling with medication to help individuals reduce or quit smoking and unhealthy alcohol consumption. The study utilizes a randomized controlled trial design to evaluate the effectiveness of these combined interventions, which have been tailored specifically for the unique challenges faced by PWH in this region. By understanding the interplay between tobacco and alcohol use, the research seeks to improve health outcomes and reduce the risk of related diseases, such as esophageal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV in Nairobi who also engage in smoking and unhealthy alcohol use.
Not a fit: Patients who do not smoke or consume alcohol may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for PWH, ultimately improving their overall health and quality of life.
How similar studies have performed: Previous research has shown promising results in addressing co-occurring substance use among PWH, indicating that this approach has potential for success.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Himelhoch, Seth S — University of Chicago
- Study coordinator: Himelhoch, Seth S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.